Table 4.

β-Blocker use compared with nonuse in relation to lung cancer–specific mortality by histology among patients diagnosed with non–small cell lung cancer in Sweden between July 1, 2006 and December 31, 2014.

All patientsEarly stage (I–II) disease
No. of eventsHRa (95% CI)No. of eventsHRa (95% CI)
In adenocarcinoma2,2101.02 (0.97–1.08)2250.93 (0.77–1.12)
In squamous cell carcinoma9451.00 (0.92–1.09)1450.93 (0.74–1.15)
In large cell carcinoma1390.99 (0.78–1.27)222.76 (1.20–6.32)
In adenosquamous carcinoma481.58 (0.94–2.65)8Not estimated
  • Note: ‘No. of events’ column shows number of outcome events among β-blocker users.

  • aAdjusted for age, sex, stage, year of diagnosis, region of residence, attained education, marital status, comorbidity score (number of distinct ATC classes prescribed during 1 year prior to diagnosis), comorbidity (coronary artery disease, heart failure, cerebrovascular disease, chronic obstructive pulmonary disease, asthma, diabetes), other antihypertensive medications, nonsteroidal anti-inflammatory drugs, aspirin, statins.